4LIFE TRANSFER FACTOR PRODUCTS APPROVED FOR USE BY OLYMPIC ATHLETES

As first reported by 4Life Chief Scientific Officer Calvin McCausland, Ph.D., in Direct Selling News, 4Life received documentation from the Federal Anti-Doping Center in Moscow, Russia, that admits 4Life Transfer Factor for use by Olympians in practice, training, and competition. Approval was obtained after volunteers consumed 4Life Transfer Factor Products and their bodily fluids were analyzed in accordance with doping control procedures that employ modern methods of gas chromatography and mass-spectrometry in compliance with the World Anti-Doping Agency in Montreal, Canada.

“We are very pleased by this approval,” commented President of Eurasia Emma Oganova, M.D., Ph.D. “4Life Transfer Factor continues to define the cutting-edge of immune system science.”

4Life Founder and Chief Executive Officer David Lisonbee launched 4Life Research in 1998 with a commitment to the highest scientific standards. Ongoing research and development of Transfer Factor technology has fueled 4Life’s constant growth and maximized every distributor’s ability to grow a successful independent business.

“Arguably, this kind of marketplace positioning and high level product messaging simply isn’t possible without the involvement of a professional research and development team,” added McCausland.

“I am pleased with our continued evolution in the supplement industry,” stated Executive Vice President Bruce Redd. “The quality work of our Research and Development department is certain to keep 4Life on the leading edge of science and success for years to come.”

4Life, the leader in the development, production, and distribution of Transfer Factor support products, continues to post growth in more than 55 countries around the world.

4LIFE TRANSFER FACTOR APPROVED BY THE HEALTH MINISTRY OF RUSSIA FOR USE IN HOSPITALS AND CLINICS!

First Ever Dietary Supplement to be Approved for Use by Doctors and Hospitals in Russia

In an unprecedented announcement in the history of network marketing, 4Life announced today that 4Life Transfer Factor products as immune modulators have been approved for use in hospitals and clinics in the Russian Federation. The results of ten separate clinical trials and two experimental studies on 4Life Transfer Factor products were combined in a Methodological Document that was approved by the Ministry of Health, which now allows doctors to recommend 4Life Transfer Factor Classic and 4Life Transfer Factor Plus® products to their patients.

First Dietary Supplement Approved for Use by Doctors and Hospitals in Russia

Commenting on this remarkable achievement, David Lisonbee, CEO of 4Life stated, “To my knowledge, this is the first time in the history of this industry that a network marketing company or any other dietary supplement company has had one of its dietary supplements approved for use in hospitals in Russia. The Russian Ministry of Health is the equivalent of the Food and Drug Administration in the United States. Doctors and scientists from Russia have been working jointly with scientists from 4Life for several years to arrive at this accomplishment. This approval establishes a new roll of dietary supplements in the Russian health care system.

 Remarkable Response from Russian Academy of Medical Sciences

In another sector of research of 4Life Transfer Factor, Dr. Kisielevsky of the Russian Academy of Medical Sciences stated, “The 4Life sample [Transfer Factor Advanced Formula] activated NK (natural killer) cell activity more than the Interleukin-2 (IL2) drug we used as the standard.” This discovery has attracted the attention of The International Scientific and Technical Center (ISTC) of Russia.

Scientists from Several Countries Join Forces for Additional Clinical Studies of Transfer Factor

The ISTC of Russia is a member of a joint international project with other health agencies of Japan, Europe and the US. The objective of the international project is to combine efforts in finding improved immunotherapies. Following the discoveries from the NK cell testing, the scientists of 4Life have been invited to join the project. 4Life Transfer Factor as an immune modulator will be further researched in this international forum. The cost of the studies will be paid by the ISTC.

Worldwide Ramification

Speaking of this benchmark achievement, Dr. Calvin McCausland, VP of Research of 4Life, and Dr. Emma Oganova, 4Life/Eurasia President, jointly expressed that because of the acceptance by such a reputable organization and doctors from Russia and other major countries, 4Life Transfer Factor will gain wider acceptance in the professional and private sectors as a superior immune system enhancing product. The worldwide ramifications to this acceptance are just beginning.